Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-10-19

AUTHORS

M. R. McClung, A. Balske, D. E. Burgio, D. Wenderoth, R. R. Recker

ABSTRACT

Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance.IntroductionThis 2-year, randomized, controlled, non-inferiority study assessed the efficacy and safety of a delayed-release (DR) 35-mg weekly oral formulation of risedronate that allows subjects to take their weekly risedronate dose before or immediately after breakfast. Results from the first year of the study were published previously (McClung et al. Osteoporos Int 23(1):267-276, 2012); we now report the final results after 2 years.MethodsWomen with postmenopausal osteoporosis were randomly assigned to receive risedronate 5 mg immediate-release (IR) daily (n = 307) at least 30 min before breakfast, or risedronate 35 mg DR weekly, either immediately following breakfast (FB, n = 307) or at least 30 min before breakfast (BB, n = 308). Bone mineral density (BMD), bone turnover markers (BTMs), fractures, adverse events, and bone histomorphometry were evaluated.ResultsA total of 248 subjects (80.8 %) in the IR daily group, 234 subjects (76.2 %) in the DR FB weekly group, and 240 subjects (77.9 %) in the DR BB weekly group completed the 2-year study. After 2 years of treatment, BMD increases at the lumbar spine and total hip with the weekly DR doses similar to or greater than that with the IR daily dose. Decreases in BTMs were similar or significantly lower in the DR groups. Bone histomorphometry results did not differ among the DR weekly and the IR daily formulations. The three regimens were similarly well tolerated.ConclusionsRisedronate 35 mg DR weekly is as effective and as well tolerated as risedronate 5 mg IR daily, and will allow subjects to take their weekly risedronate dose immediately after breakfast. More... »

PAGES

301-310

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00198-012-2175-7

DOI

http://dx.doi.org/10.1007/s00198-012-2175-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1044083426

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23079690


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Delayed-Action Preparations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Etidronic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Femur", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hip Joint", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lumbar Vertebrae", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis, Postmenopausal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risedronic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, 97213, Portland, OR, USA", 
          "id": "http://www.grid.ac/institutes/grid.240531.1", 
          "name": [
            "Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, 97213, Portland, OR, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McClung", 
        "givenName": "M. R.", 
        "id": "sg:person.01202365465.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202365465.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Abbott Laboratories, Abbott Park, IL, USA", 
          "id": "http://www.grid.ac/institutes/grid.417574.4", 
          "name": [
            "Abbott Laboratories, Abbott Park, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Balske", 
        "givenName": "A.", 
        "id": "sg:person.01026402633.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026402633.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Procter and Gamble Company, Mason, OH, USA", 
          "id": "http://www.grid.ac/institutes/grid.418758.7", 
          "name": [
            "The Procter and Gamble Company, Mason, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burgio", 
        "givenName": "D. E.", 
        "id": "sg:person.01074516033.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074516033.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Warner Chilcott Deutschland GmbH, Weiterstadt, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Warner Chilcott Deutschland GmbH, Weiterstadt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wenderoth", 
        "givenName": "D.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Osteoporosis Research Center, Creighton University, Omaha, NE, USA", 
          "id": "http://www.grid.ac/institutes/grid.254748.8", 
          "name": [
            "Osteoporosis Research Center, Creighton University, Omaha, NE, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Recker", 
        "givenName": "R. R.", 
        "id": "sg:person.016325222544.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016325222544.69"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s002230001146", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004533024", 
          "https://doi.org/10.1007/s002230001146"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-009-0893-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037232817", 
          "https://doi.org/10.1007/s00198-009-0893-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00223-002-2104-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026675556", 
          "https://doi.org/10.1007/s00223-002-2104-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00223-003-0042-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034121766", 
          "https://doi.org/10.1007/s00223-003-0042-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-012-2056-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035221448", 
          "https://doi.org/10.1007/s00198-012-2056-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00223-004-0039-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046491481", 
          "https://doi.org/10.1007/s00223-004-0039-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00223-004-0286-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007415759", 
          "https://doi.org/10.1007/s00223-004-0286-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001980050010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005303812", 
          "https://doi.org/10.1007/s001980050010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-011-1791-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040344660", 
          "https://doi.org/10.1007/s00198-011-1791-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-10-19", 
    "datePublishedReg": "2012-10-19", 
    "description": "Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance.IntroductionThis 2-year, randomized, controlled, non-inferiority study assessed the efficacy and safety of a delayed-release (DR) 35-mg weekly oral formulation of risedronate that allows subjects to take their weekly risedronate dose before or immediately after breakfast. Results from the first year of the study were published previously (McClung et al. Osteoporos Int 23(1):267-276, 2012); we now report the final results after 2\u00a0years.MethodsWomen with postmenopausal osteoporosis were randomly assigned to receive risedronate 5\u00a0mg immediate-release (IR) daily (n\u2009=\u2009307) at least 30\u00a0min before breakfast, or risedronate 35\u00a0mg DR weekly, either immediately following breakfast (FB, n\u2009=\u2009307) or at least 30\u00a0min before breakfast (BB, n\u2009=\u2009308). Bone mineral density (BMD), bone turnover markers (BTMs), fractures, adverse events, and bone histomorphometry were evaluated.ResultsA total of 248 subjects (80.8\u00a0%) in the IR daily group, 234 subjects (76.2\u00a0%) in the DR FB weekly group, and 240 subjects (77.9\u00a0%) in the DR BB weekly group completed the 2-year study. After 2\u00a0years of treatment, BMD increases at the lumbar spine and total hip with the weekly DR doses similar to or greater than that with the IR daily dose. Decreases in BTMs were similar or significantly lower in the DR groups. Bone histomorphometry results did not differ among the DR weekly and the IR daily formulations. The three regimens were similarly well tolerated.ConclusionsRisedronate 35\u00a0mg DR weekly is as effective and as well tolerated as risedronate 5\u00a0mg IR daily, and will allow subjects to take their weekly risedronate dose immediately after breakfast.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00198-012-2175-7", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1100834", 
        "issn": [
          "0937-941X", 
          "1433-2965"
        ], 
        "name": "Osteoporosis International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "keywords": [
      "bone turnover markers", 
      "bone mineral density", 
      "risedronate 5", 
      "postmenopausal osteoporosis", 
      "weekly group", 
      "bone mineral density response", 
      "oral bisphosphonate therapy", 
      "non-inferiority study", 
      "years of treatment", 
      "delayed-release formulation", 
      "bisphosphonate therapy", 
      "risedronate 35", 
      "turnover markers", 
      "adverse events", 
      "daily group", 
      "daily dose", 
      "total hip", 
      "DR group", 
      "daily formulation", 
      "poor compliance", 
      "ResultsA total", 
      "mineral density", 
      "bone histomorphometry", 
      "lumbar spine", 
      "oral formulation", 
      "risedronate", 
      "breakfast", 
      "weekly", 
      "dose", 
      "osteoporosis", 
      "histomorphometry results", 
      "first year", 
      "subjects", 
      "treatment", 
      "group", 
      "years", 
      "regimen", 
      "MethodsWomen", 
      "regimens", 
      "therapy", 
      "min", 
      "hip", 
      "histomorphometry", 
      "doses", 
      "daily", 
      "spine", 
      "study", 
      "IntroductionThis", 
      "efficacy", 
      "total", 
      "markers", 
      "safety", 
      "fractures", 
      "compliance", 
      "response", 
      "decrease", 
      "results", 
      "events", 
      "final results", 
      "formulation", 
      "density response", 
      "density", 
      "IR"
    ], 
    "name": "Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years", 
    "pagination": "301-310", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1044083426"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00198-012-2175-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23079690"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00198-012-2175-7", 
      "https://app.dimensions.ai/details/publication/pub.1044083426"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_560.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00198-012-2175-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-012-2175-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-012-2175-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-012-2175-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-012-2175-7'


 

This table displays all metadata directly associated to this object as RDF triples.

267 TRIPLES      21 PREDICATES      114 URIs      97 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00198-012-2175-7 schema:about N03c6a2ae9714441789c11f39dc416069
2 N0420a7dd3a7b471c84f46c10b1855607
3 N23a5a427a06f4ac8a066926846441f40
4 N25992748d9a346299ae12deee5a1de3c
5 N2975d17076ea423383958c8c43b40a61
6 N2a50f055ad4c4772868bedbb89c491d7
7 N3316eef5494d4a829dfa0168493fed9b
8 N3d42ceacd3b94434916b37bf3af3462f
9 N3f22b30074ae44a2becfc75539b220da
10 N40db0d5109684dafbd366302f0349e3c
11 N81356218d2d949b9962d7a5573117de7
12 N9677927b21e0443486241137b88142ce
13 Na2205aa1fe5246089d074f483e97e98b
14 Ncc8e0308bdc840f7ba18a7129b755087
15 Ne19878d516f6439aa44d52babe17f43f
16 Nf766702bcab346d08e4ba801c0a09beb
17 Nfdfabe01f0af4991b284032b038d55ff
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author Neb38b1c77f4f44e1a4c6e0ec4840da27
21 schema:citation sg:pub.10.1007/s00198-009-0893-2
22 sg:pub.10.1007/s00198-011-1791-y
23 sg:pub.10.1007/s00198-012-2056-0
24 sg:pub.10.1007/s001980050010
25 sg:pub.10.1007/s00223-002-2104-4
26 sg:pub.10.1007/s00223-003-0042-4
27 sg:pub.10.1007/s00223-004-0039-7
28 sg:pub.10.1007/s00223-004-0286-7
29 sg:pub.10.1007/s002230001146
30 schema:datePublished 2012-10-19
31 schema:datePublishedReg 2012-10-19
32 schema:description Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance.IntroductionThis 2-year, randomized, controlled, non-inferiority study assessed the efficacy and safety of a delayed-release (DR) 35-mg weekly oral formulation of risedronate that allows subjects to take their weekly risedronate dose before or immediately after breakfast. Results from the first year of the study were published previously (McClung et al. Osteoporos Int 23(1):267-276, 2012); we now report the final results after 2 years.MethodsWomen with postmenopausal osteoporosis were randomly assigned to receive risedronate 5 mg immediate-release (IR) daily (n = 307) at least 30 min before breakfast, or risedronate 35 mg DR weekly, either immediately following breakfast (FB, n = 307) or at least 30 min before breakfast (BB, n = 308). Bone mineral density (BMD), bone turnover markers (BTMs), fractures, adverse events, and bone histomorphometry were evaluated.ResultsA total of 248 subjects (80.8 %) in the IR daily group, 234 subjects (76.2 %) in the DR FB weekly group, and 240 subjects (77.9 %) in the DR BB weekly group completed the 2-year study. After 2 years of treatment, BMD increases at the lumbar spine and total hip with the weekly DR doses similar to or greater than that with the IR daily dose. Decreases in BTMs were similar or significantly lower in the DR groups. Bone histomorphometry results did not differ among the DR weekly and the IR daily formulations. The three regimens were similarly well tolerated.ConclusionsRisedronate 35 mg DR weekly is as effective and as well tolerated as risedronate 5 mg IR daily, and will allow subjects to take their weekly risedronate dose immediately after breakfast.
33 schema:genre article
34 schema:isAccessibleForFree true
35 schema:isPartOf N203ef4962c7e49458db34ee04bf9c191
36 N331445902af64c8dbd1f9aef3e3440fe
37 sg:journal.1100834
38 schema:keywords DR group
39 IR
40 IntroductionThis
41 MethodsWomen
42 ResultsA total
43 adverse events
44 bisphosphonate therapy
45 bone histomorphometry
46 bone mineral density
47 bone mineral density response
48 bone turnover markers
49 breakfast
50 compliance
51 daily
52 daily dose
53 daily formulation
54 daily group
55 decrease
56 delayed-release formulation
57 density
58 density response
59 dose
60 doses
61 efficacy
62 events
63 final results
64 first year
65 formulation
66 fractures
67 group
68 hip
69 histomorphometry
70 histomorphometry results
71 lumbar spine
72 markers
73 min
74 mineral density
75 non-inferiority study
76 oral bisphosphonate therapy
77 oral formulation
78 osteoporosis
79 poor compliance
80 postmenopausal osteoporosis
81 regimen
82 regimens
83 response
84 results
85 risedronate
86 risedronate 35
87 risedronate 5
88 safety
89 spine
90 study
91 subjects
92 therapy
93 total
94 total hip
95 treatment
96 turnover markers
97 weekly
98 weekly group
99 years
100 years of treatment
101 schema:name Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
102 schema:pagination 301-310
103 schema:productId N2e2a92f0f080433482bbbbd7ad00c0f4
104 N3bb92963f24745fa8fc63669ff4082ab
105 N707fe3f750744628983434b04fc0e989
106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044083426
107 https://doi.org/10.1007/s00198-012-2175-7
108 schema:sdDatePublished 2022-08-04T16:59
109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
110 schema:sdPublisher N20628154411c43c3893a471aeb836933
111 schema:url https://doi.org/10.1007/s00198-012-2175-7
112 sgo:license sg:explorer/license/
113 sgo:sdDataset articles
114 rdf:type schema:ScholarlyArticle
115 N03c6a2ae9714441789c11f39dc416069 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Administration, Oral
117 rdf:type schema:DefinedTerm
118 N0420a7dd3a7b471c84f46c10b1855607 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Female
120 rdf:type schema:DefinedTerm
121 N0496ada5bc8f4746b278d44d624cf3b1 rdf:first sg:person.016325222544.69
122 rdf:rest rdf:nil
123 N203ef4962c7e49458db34ee04bf9c191 schema:volumeNumber 24
124 rdf:type schema:PublicationVolume
125 N20628154411c43c3893a471aeb836933 schema:name Springer Nature - SN SciGraph project
126 rdf:type schema:Organization
127 N23a5a427a06f4ac8a066926846441f40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Etidronic Acid
129 rdf:type schema:DefinedTerm
130 N25992748d9a346299ae12deee5a1de3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Treatment Outcome
132 rdf:type schema:DefinedTerm
133 N2975d17076ea423383958c8c43b40a61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Femur
135 rdf:type schema:DefinedTerm
136 N2a50f055ad4c4772868bedbb89c491d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Bone Density Conservation Agents
138 rdf:type schema:DefinedTerm
139 N2e2a92f0f080433482bbbbd7ad00c0f4 schema:name doi
140 schema:value 10.1007/s00198-012-2175-7
141 rdf:type schema:PropertyValue
142 N331445902af64c8dbd1f9aef3e3440fe schema:issueNumber 1
143 rdf:type schema:PublicationIssue
144 N3316eef5494d4a829dfa0168493fed9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Middle Aged
146 rdf:type schema:DefinedTerm
147 N3bb92963f24745fa8fc63669ff4082ab schema:name dimensions_id
148 schema:value pub.1044083426
149 rdf:type schema:PropertyValue
150 N3d42ceacd3b94434916b37bf3af3462f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Hip Joint
152 rdf:type schema:DefinedTerm
153 N3f22b30074ae44a2becfc75539b220da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Delayed-Action Preparations
155 rdf:type schema:DefinedTerm
156 N40db0d5109684dafbd366302f0349e3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Double-Blind Method
158 rdf:type schema:DefinedTerm
159 N707fe3f750744628983434b04fc0e989 schema:name pubmed_id
160 schema:value 23079690
161 rdf:type schema:PropertyValue
162 N81356218d2d949b9962d7a5573117de7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Bone Density
164 rdf:type schema:DefinedTerm
165 N9677927b21e0443486241137b88142ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Aged
167 rdf:type schema:DefinedTerm
168 N9e27c7f7debb4714823554de5025641e rdf:first Ncb439a3a33724433b7a5ec2169b3076d
169 rdf:rest N0496ada5bc8f4746b278d44d624cf3b1
170 N9fa8025d8348497cb26c088deb8f772b rdf:first sg:person.01074516033.39
171 rdf:rest N9e27c7f7debb4714823554de5025641e
172 Na2205aa1fe5246089d074f483e97e98b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Osteoporosis, Postmenopausal
174 rdf:type schema:DefinedTerm
175 Na2b5b9b61fa142e386043a7290c5e412 rdf:first sg:person.01026402633.23
176 rdf:rest N9fa8025d8348497cb26c088deb8f772b
177 Ncb439a3a33724433b7a5ec2169b3076d schema:affiliation grid-institutes:None
178 schema:familyName Wenderoth
179 schema:givenName D.
180 rdf:type schema:Person
181 Ncc8e0308bdc840f7ba18a7129b755087 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Humans
183 rdf:type schema:DefinedTerm
184 Ne19878d516f6439aa44d52babe17f43f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Drug Administration Schedule
186 rdf:type schema:DefinedTerm
187 Neb38b1c77f4f44e1a4c6e0ec4840da27 rdf:first sg:person.01202365465.00
188 rdf:rest Na2b5b9b61fa142e386043a7290c5e412
189 Nf766702bcab346d08e4ba801c0a09beb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Lumbar Vertebrae
191 rdf:type schema:DefinedTerm
192 Nfdfabe01f0af4991b284032b038d55ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Risedronic Acid
194 rdf:type schema:DefinedTerm
195 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
196 schema:name Medical and Health Sciences
197 rdf:type schema:DefinedTerm
198 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
199 schema:name Clinical Sciences
200 rdf:type schema:DefinedTerm
201 sg:journal.1100834 schema:issn 0937-941X
202 1433-2965
203 schema:name Osteoporosis International
204 schema:publisher Springer Nature
205 rdf:type schema:Periodical
206 sg:person.01026402633.23 schema:affiliation grid-institutes:grid.417574.4
207 schema:familyName Balske
208 schema:givenName A.
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026402633.23
210 rdf:type schema:Person
211 sg:person.01074516033.39 schema:affiliation grid-institutes:grid.418758.7
212 schema:familyName Burgio
213 schema:givenName D. E.
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074516033.39
215 rdf:type schema:Person
216 sg:person.01202365465.00 schema:affiliation grid-institutes:grid.240531.1
217 schema:familyName McClung
218 schema:givenName M. R.
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202365465.00
220 rdf:type schema:Person
221 sg:person.016325222544.69 schema:affiliation grid-institutes:grid.254748.8
222 schema:familyName Recker
223 schema:givenName R. R.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016325222544.69
225 rdf:type schema:Person
226 sg:pub.10.1007/s00198-009-0893-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037232817
227 https://doi.org/10.1007/s00198-009-0893-2
228 rdf:type schema:CreativeWork
229 sg:pub.10.1007/s00198-011-1791-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1040344660
230 https://doi.org/10.1007/s00198-011-1791-y
231 rdf:type schema:CreativeWork
232 sg:pub.10.1007/s00198-012-2056-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035221448
233 https://doi.org/10.1007/s00198-012-2056-0
234 rdf:type schema:CreativeWork
235 sg:pub.10.1007/s001980050010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005303812
236 https://doi.org/10.1007/s001980050010
237 rdf:type schema:CreativeWork
238 sg:pub.10.1007/s00223-002-2104-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026675556
239 https://doi.org/10.1007/s00223-002-2104-4
240 rdf:type schema:CreativeWork
241 sg:pub.10.1007/s00223-003-0042-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034121766
242 https://doi.org/10.1007/s00223-003-0042-4
243 rdf:type schema:CreativeWork
244 sg:pub.10.1007/s00223-004-0039-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046491481
245 https://doi.org/10.1007/s00223-004-0039-7
246 rdf:type schema:CreativeWork
247 sg:pub.10.1007/s00223-004-0286-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007415759
248 https://doi.org/10.1007/s00223-004-0286-7
249 rdf:type schema:CreativeWork
250 sg:pub.10.1007/s002230001146 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004533024
251 https://doi.org/10.1007/s002230001146
252 rdf:type schema:CreativeWork
253 grid-institutes:None schema:alternateName Warner Chilcott Deutschland GmbH, Weiterstadt, Germany
254 schema:name Warner Chilcott Deutschland GmbH, Weiterstadt, Germany
255 rdf:type schema:Organization
256 grid-institutes:grid.240531.1 schema:alternateName Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, 97213, Portland, OR, USA
257 schema:name Oregon Osteoporosis Center, 5050 NE Hoyt, Suite 626, 97213, Portland, OR, USA
258 rdf:type schema:Organization
259 grid-institutes:grid.254748.8 schema:alternateName Osteoporosis Research Center, Creighton University, Omaha, NE, USA
260 schema:name Osteoporosis Research Center, Creighton University, Omaha, NE, USA
261 rdf:type schema:Organization
262 grid-institutes:grid.417574.4 schema:alternateName Abbott Laboratories, Abbott Park, IL, USA
263 schema:name Abbott Laboratories, Abbott Park, IL, USA
264 rdf:type schema:Organization
265 grid-institutes:grid.418758.7 schema:alternateName The Procter and Gamble Company, Mason, OH, USA
266 schema:name The Procter and Gamble Company, Mason, OH, USA
267 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...